Innovate UK

Constructive Bio is a biotechnology company focused on genome rewriting to unlock new possibilities in bioprocesses and biopharmaceuticals. The company transforms living cells into biofactories, producing sustainable materials and therapeutics. By harnessing advanced technologies, Constructive Bio creates virus-resistant organisms and biosynthesizes a range of enzymes, pharmaceuticals, and biomaterials. This innovative approach allows clients to reprogram genetic codes, enabling the creation of natural molecules that were previously inaccessible through conventional biology. Through its unique capabilities, Constructive Bio aims to lead the development of the next generation of sustainable solutions in the life sciences.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

MediMusic is a health technology company that focuses on developing a medical technology platform aimed at alleviating pain, anxiety, and stress through the power of music. The platform leverages artificial intelligence to generate personalized playlists tailored to individual patient needs. By using soothing music, MediMusic's solution aims to lower heart rates and stimulate the vagus nerve, promoting a positive physiological response. This innovative approach not only helps in managing stress and anxiety but also enhances the effectiveness of pain medication, offering a holistic treatment option for patients dealing with various health challenges, including dementia and anxiety-related disorders.

Epitopea is a biotechnology company focused on developing innovative immunotherapies for cancer treatment by targeting a new class of tumor-specific antigens. The company employs a proprietary approach that combines immunopeptidomics, mass spectrometry, genomics, and bioinformatics to identify conserved, aberrantly expressed tumor-specific antigens hidden within cancer's non-coding DNA. This technology aims to create therapies that effectively eliminate malignant cells while minimizing damage to healthy tissue, thereby reducing side effects and providing lasting benefits for patients. Research conducted by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal has been instrumental in the discovery of these novel antigens, known as Cryptigen™ TSAs, which are shared among patients with the same cancer type.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

ThirtyFiveBio is a biotechnology agency focused on developing innovative protein modulators aimed at treating severe gastrointestinal diseases, which represent a significant unmet clinical need. The company specializes in genetically and pharmacologically validated modulators that facilitate a comprehensive drug discovery program. This program is designed to identify small-molecule modulators of specific proteins, with the potential to impact a wide range of digestive system malignancies. By targeting GPR35 signaling, ThirtyFiveBio's approach aims to provide therapeutic options that may help in preventing tumor growth associated with gastrointestinal cancers.

Nuclera specializes in providing a protein prototyping system designed to enhance drug discovery by making proteins readily accessible to researchers. The company's eProtein Discovery system enables scientists to quickly produce and evaluate proteins, thus accelerating their research efforts. Nuclera's automated platform delivers reliable, high-quality, and soluble proteins within a specified timeframe, facilitating the scale-up of protein projects. The integration of technology, including cell-free protein synthesis and digital microfluidics on smart cartridges, allows for efficient, high-throughput access to proteins. This streamlined approach supports researchers in advancing their protein projects more rapidly and effectively.

Fuse Diagnostics focuses on manufacturing diagnostic products that deliver lab-quality information across various sectors. The company aims to provide innovative and cost-effective testing solutions that ensure laboratory accuracy for applications in food and water testing, bioprocessing, and cell biology research. By offering low-cost test kits equipped with integrated readout technology, Fuse Diagnostics enables businesses to obtain rapid and reliable results, thereby enhancing the accessibility and efficiency of diagnostic testing.

LIfT BioSciences is a biotechnology company based in London, England, founded in 2016. The company specializes in a novel allogeneic innate immuno-cell therapy platform known as Neutrophil Only Leukocyte Infusion Therapy (N-LIfT). This platform enables the large-scale production of Immunomodulatory Alpha Neutrophils (IMANs) derived from induced pluripotent stem cells (iPSCs) for various therapeutic applications. LIfT BioSciences focuses on developing CAR neutrophil cell therapies that address the limitations of existing treatments for solid tumors. These therapies work by directly attacking tumors and indirectly enhancing the immune response, effectively transforming the tumor microenvironment to recruit additional immune cells for a more robust and lasting attack on the cancer. By employing proprietary enhancement media and genetic engineering, LIfT BioSciences aims to significantly increase the cancer-fighting capabilities of these engineered cells, potentially providing patients with greatly improved therapeutic outcomes.

Monument Therapeutics is a biotechnology company intended to develop drugs to treat serious diseases of the central nervous system.

Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.

Presymptom Health develops a portfolio of clinical decision support algorithms and blood tests to enable early intervention and transform critical care outcomes.

Cortirio specializes in the development of portable brain imaging technology aimed at diagnosing and monitoring traumatic brain injuries, which are a leading cause of death and disability among individuals under 40. The company's innovative portable scanners utilize near-infrared imaging with enhanced spatial resolution to deliver point-of-care medical imaging. This technology enables healthcare providers to access vital information throughout the clinical pathway, facilitating automatic analysis and data transfer. By providing timely and accurate diagnostic capabilities, Cortirio's devices empower clinicians to make quicker decisions, ultimately improving care for patients suffering from brain injuries and strokes.

IXICO is a UK-based company specializing in clinical trial services and technology focused on imaging endpoints for the pharmaceutical and biotechnology sectors. The company primarily operates in the fields of oncology and neurology, offering end-to-end imaging services that cater to various therapeutic areas, including Alzheimer's, Parkinson's, Huntington's disease, and other neurodegenerative conditions. IXICO supports clients throughout the entire clinical research journey, providing services for early and late-phase clinical development, post-marketing assessments, and consultancy. With a presence in multiple countries, including the United States, Switzerland, the Netherlands, and Ireland, IXICO collaborates with pharmaceutical companies, academia, and medical charities to advance the treatment of complex diseases.

SolasCure Limited is a biotechnology company based in Wales, United Kingdom, focused on developing innovative solutions for patients with chronic wounds. Founded in 2017, the company is advancing its product Aurase, a hydrogel designed to facilitate wound debridement by removing dead, damaged, or infected tissue to enhance healing. Aurase incorporates a recombinant enzyme derived from maggots, leveraging biomimicry and evidence-based medicine to improve wound care outcomes. SolasCure aims to provide effective wound bed preparation across various healthcare settings, ultimately accelerating the healing process for individuals suffering from chronic wounds.

Aelius Biotech specializes in creating advanced models of the mucosal surfaces of the human body. The company focuses on developing systems that simulate the gastrointestinal tract and airways, with ongoing efforts to model the eye and cervico-vaginal tract. Aelius Biotech's model gut system allows healthcare industry participants to simulate essential processes such as digestion, mucus permeation, and epithelial absorption. The company provides a range of testing services, including in vitro and in vivo assessments, simple lab assays, and integrated model gut testing across the aerodigestive tract. Additionally, Aelius Biotech conducts human trials, aiding healthcare companies in making informed, data-driven decisions to enhance and de-risk the development of orally delivered products.

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

Mesenbio is a preclinical biopharmaceutical company located at the University of York, specializing in cell-derived therapies. It employs a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which enhances the development of treatments by addressing common challenges in extracellular vesicle therapy. The company is focused on creating innovative treatments for conditions such as arthritis, utilizing engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio aims to improve access to effective therapies for musculoskeletal diseases, thereby contributing to advancements in medical treatment.

The University of Edinburgh, established in 1583, is the sixth-oldest university in the English-speaking world and one of Scotland's ancient universities. Recognized as one of the most prestigious institutions globally, it offers a diverse range of academic programs across various disciplines, including notable schools such as the Medical School and the Law School. The university is dedicated to excellence in teaching and research, attracting students and scholars from around the world. Its rich history and commitment to innovation make it a key player in higher education, contributing significantly to academic and societal advancements.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

CellRev is a biotechnology company specializing in innovative bioprocessing technologies aimed at improving cell manufacturing for various applications, including cultured meat, cell therapy, and biologics. The company's proprietary technology enables a shift from traditional batch processing to continuous processing of adherent cells, significantly enhancing yield while reducing operating costs and capital expenditures. CellRev's unique cell detachment process, combined with a specially designed bioprocess, addresses critical challenges in manufacturing, such as cell aggregation, clumping, and detachment. This approach allows cell-based vaccine and therapy developers to streamline their production processes, eliminate serum usage, and overcome significant bottlenecks in the industry.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

Spirecut is a MedTech company specializing in innovative surgical instruments designed for the treatment of carpal tunnel syndrome and trigger finger. The company has developed a patented technique for ultrasound-guided surgery that eliminates the need for skin incisions, resulting in no post-operative wounds. This approach allows patients to resume daily activities immediately without the need for dressings or coverings on the operated area. Spirecut's instruments represent a significant advancement over traditional methods, improving upon the simple needles typically used by surgeons and radiologists. The enhanced design facilitates the safe release of thickened tissue and aids in preoperative sonographic tracking, ultimately enabling surgeons to achieve better surgical outcomes and accelerating patient recovery.

Laverock Therapeutics is focused on advancing gene silencing technology to create innovative programmable cell therapies. Their platform enables the engineering of next-generation allogeneic cell therapies that can adapt to both internal and external environmental signals. This capability allows for the development of induced pluripotent stem cell (iPSC)-derived products that offer enhanced efficacy, safety, and accessibility, addressing many of the challenges faced by traditional therapeutic methods. Through its pioneering approach, Laverock Therapeutics aims to facilitate significant advancements in the fields of medicine and biotechnology.

Brainomix Limited, established in 2010 as a spin-out from the University of Oxford, develops advanced imaging biomarkers and software solutions aimed at enhancing clinical decision-making for neurological and cerebrovascular disorders. The company's flagship product, e-Stroke, employs state-of-the-art artificial intelligence algorithms to automate the interpretation of brain scans, specifically for acute ischemic stroke patients. This tool assists physicians in identifying and quantifying early stroke damage, thereby facilitating timely and informed treatment decisions. In addition to e-Stroke, Brainomix offers other software products such as e-ASPECTS, which automates the Alberta Stroke Program Early CT Score, and e-CTA, which standardizes the assessment of large vessel occlusion locations. These innovative solutions address the critical need for rapid and consistent evaluations of brain CT scans, ultimately optimizing patient outcomes and ensuring that stroke patients receive appropriate care in a timely manner. The company is headquartered in Oxford, United Kingdom.

Stablepharma Ltd specializes in developing innovative processes for vaccine stabilization, focusing on its technology platform, StablevaX™, which transforms existing approved vaccines, therapeutics, and diagnostics into thermostable products that do not require refrigeration. This advancement addresses the global challenges associated with cold chain logistics, allowing for efficient and waste-free vaccine delivery. The company has identified up to 60 vaccine candidates suitable for its technology and collaborates with global vaccine manufacturers, academic institutions, and non-governmental organizations to enhance its pipeline of thermostable products. Founded in 2012 and based in Bath, United Kingdom, Stablepharma aims to reduce costs and carbon emissions while expanding access to vaccines for both children and adults.

Jude is a healthcare company focused on addressing bladder health issues and raising awareness about incontinence. The organization offers a range of services that include expert advice from medical professionals through social media, virtual seminars, and private chat options. Additionally, Jude provides health products designed to assist individuals in managing their bladder health effectively. By combining educational resources with accessible support, Jude aims to empower individuals to understand their medical conditions and pursue solutions for a leak-free life.

Ramanomics extracts microorganisms and their antimicrobial profiles from clinical specimens.

Corryn Biotechnologies is a biotechnology company focused on innovating wound care solutions through its Heals device, which offers a contactless method for treating chronic and complex wounds. The company has developed advanced applicators that utilize electrical voltages to extrude fine fibers from various fluids, creating wound dressings that can be made from synthetic or natural materials. These dressings can be enhanced with or without active ingredients and are designed to deposit non-woven meshes for effective Advanced Tissue Repair (ATR). Through this technology, Corryn aims to improve the management and healing of chronic wounds, providing a novel approach to wound dressing.

We are a team of matrix biologists, cancer scientists, toxicologists, and biomaterial engineers who have worked together to develop an innovative, animal-free solution for 3D cell culture. We have done this with the support of the NC3Rs, BBSRC, and EPSRC. By combining the skills and expertise of individuals across a broad range of scientific backgrounds we are able to develop technologies that address a variety of unmet challenges in 3D in vitro modelling. Our mission is to provide researchers a better way to model development and disease that is more reproducible, reliable, and ethical. To learn more, visit www.peptimatrix.com

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

SMi Systems is a biomedical research and medical equipment manufacturing organization specializing in the development of advanced diagnostic and discovery tools. Their high-performance diagnostic devices, capable of detecting diseases within the first 24 hours of infection, can simultaneously identify multiple conditions. By automating and enhancing throughput, these tools significantly reduce processing time for patient samples. Additionally, SMi Systems' technology enables scientists to measure critical molecular interactions associated with various diseases, allowing for a deeper understanding of therapeutic mechanisms. This capability supports extensive scientific research and clinical diagnostics across numerous disease areas, facilitating the observation of diverse molecular interactions and the monitoring of drug binding to targets.

Autolomous Ltd, founded in 2019 and based in Mayfair, United Kingdom, specializes in developing software solutions for manufacturers of cell and gene therapies. Its flagship platform, autoloMATE®, is a cloud-native system that provides comprehensive support for Advanced Therapies and Vector manufacturing processes. The software facilitates the scheduling of patient cell collections, the transport of these cells to production sites, and the tracking of manufacturing processes to ensure compliance with regulatory standards. It also supports the legal release and timely delivery of patient-specific medicines. The highly configurable platform allows clients to customize workflows and integrates seamlessly with existing systems. Autolomous emphasizes data security by utilizing blockchain technology to maintain the integrity of manufacturing data. The company adheres to strict regulatory guidelines and has achieved several ISO certifications, reflecting its commitment to quality management and environmental standards.

The Cell and Gene Therapy Catapult is a UK-based center dedicated to fostering innovation in the cell and gene therapy sector. Supported by Innovate UK, its primary objective is to accelerate the development of commercially viable therapies by assisting organizations in translating early-stage research into market-ready products. The Catapult employs over 120 experts in cell and gene therapy and features advanced laboratories for development and viral vector research. Additionally, it is in the process of establishing a £55 million large-scale Good Manufacturing Practice (GMP) manufacturing center to facilitate the market introduction of cell and gene therapies both in the UK and internationally. By offering expertise in clinical trials, process development, manufacturing, regulatory affairs, health economics, and market access, the Catapult aims to help research organizations achieve full-scale commercialization of their therapies.

GG Care helps care residents stay independent and help carers monitor their well-being, comfort, and mood. They serve people with dementia maintain daily routines and stay socially connections shown to reduce cognitive decline and increase happiness and creates an environment to help reduce agitation - significantly reducing the cost of care.

The Sixth Sense in medical Diagnostics. At AINOSTICS we are working to identify the earliest biological signs of some of our society’s most devastating neurodegenerative conditions such as Alzheimer’s disease, Huntington's and MS, providing the best chance of success in the development of potential preventions and therapeutics by Pharma, and precise treatment planning by clinicians. We combine the most exciting medical imaging innovations with the best of artificial intelligence solutions to unlock the future of personalised diagnosis, prognosis, and therapy monitoring and planning.

ScubaTx focuses on developing an organ preservation system that utilizes the Persufflation method, which is known for its effectiveness in preserving organs during transportation. By enhancing the condition of grafts during preservation, ScubaTx enables healthcare providers to expand the availability of viable organs for transplantation. The company aims to improve organ preservation practices through innovative software design, ultimately delivering significant cost savings to healthcare providers. This advancement not only enhances the quality of organ transplants but also contributes to increasing the overall supply of life-saving organs available to patients in need.

Lindus Health is a clinical research organization focused on delivering comprehensive clinical trial services for health and biotech companies. The company offers a range of solutions, including ethics and IRB submission, trial monitoring, data management, biostatistics, regulatory support, and payer affairs. By utilizing a proprietary software platform, Lindus Health automates various aspects of the clinical trial workflow, which streamlines operations and minimizes manual inefficiencies. This platform also facilitates access to electronic health records, enhancing patient recruitment and clinical data capture. Furthermore, Lindus Health leverages real-world patient data to improve trial design and execution, ultimately aiming to accelerate the clinical trial process while reducing risks and costs associated with trial failures.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.

Vitarka Therapeutics develops medical technology and solutions for various types of cancer. It is based in London, United Kingdom.

Nanovery Limited, founded in 2018 and based in London, United Kingdom, specializes in developing nanorobots aimed at detecting cancer mutations. The company's innovative platform utilizes artificial intelligence to facilitate the rapid and ultra-sensitive identification of challenging biomarkers in blood samples. These nanorobots can capture circulating tumor DNA and emit a fluorescent signal, enabling healthcare professionals to conduct point-of-care tests. By facilitating early cancer detection, Nanovery aims to enhance patient outcomes and increase survival rates. The organization is supported by a team of experts in nanotechnology, medicinal chemistry, and artificial intelligence, along with backing from leading academics, clinicians, and industry leaders.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Doctoria is a virtual healthcare platform to enable doctors and patients to connect better.

Lightox specializes in developing advanced molecular tools for imaging, therapeutics, and assay development, focusing on innovative cancer treatments. The company has created a range of light-activated drug compounds designed to selectively target and eliminate tumor cells while minimizing harm to surrounding healthy tissue. Their unique fluorescent probes are smaller than any other products currently available, allowing for versatile applications in research and clinical settings. These probes can function as freely-moving agents that easily integrate into cells, or they can be customized with flexible linkers to meet specific research requirements. Lightox aims to enhance patient outcomes by providing more efficient cancer treatment options.

Myma Medical is a bright, cutting-edge start-up with a model to greatly improve the experiences of people who are having fertility issues.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

EnsiliTech is a biopharmaceutical company focused on preserving the integrity of vaccines and other biological materials. It has developed a healthcare technology that aims to prevent vaccine spoilage through a novel ensilication process. This technology involves the growth of protective silica nanoshells on the surface of vaccine components, which helps safeguard a variety of biomolecules from environmental degradation. By enhancing the shelf-life of vaccines, EnsiliTech's platform enables clients to minimize wastage and improve global vaccine accessibility.

Healthera operates a comprehensive healthcare marketplace in the UK, connecting patients with medicines, healthcare services, and products through a vast digital platform that includes both national pharmacy chains and independent providers. The company's technology facilitates quicker medicine delivery and personalized medical care tailored to individual needs. By reinventing the pharmacy operating model, Healthera enhances patient communication, encourages cross-sales, and fosters customer loyalty. The company is dedicated to digitizing and automating primary care processes, which improves prescribing efficiency and the overall patient experience while minimizing waste for the NHS. Partnering with over 1,000 pharmacies and clinical commissioning groups, Healthera reaches more than 20 million individuals. Its technology is accredited by NHS Digital, positioning Healthera as one of the fastest-growing digital health firms in Europe. Headquartered in Cambridge, the company boasts a diverse international team committed to improving healthcare delivery through human-centered technology.

NIQS Tech is a quantum technology spin-out from the University of Leeds that is focused on delivering truly non-invasive, continuous, and accurate glucose monitoring technologies - diabetes management with no needles or blood. Accessible, user-friendly glucose monitors will provide actionable insights and enable effective diabetes management. Ultimately, NIQS aims to empower people living with diabetes to live happier and healthier lives by removing the need for cumbersome glucose management technologies and reducing their risk of diabetes-related complications.

Amber Therapeutics develops the next-generation of bioelectrical therapies that can sense and adapt as well as stimulate, with the potential to radically improve clinical outcomes in patients with functional disorders of the peripheral nervous system.

The National Biofilms Innovation Centre (NBIC) is the central hub where academia, industry, government, and public policy come together to tackle the grand challenges biofilms present, impacting ~$5 trillion in global economic activity, from food and health to ships, clean water and energy. Funded by the BBSRC, Innovate UK and Hartree Centre, our mission is to establish a network of research and innovation capacity to catalyse partnerships with industry to achieve breakthrough innovations and impact – from industry products and solutions to services and spinouts. We aim to bring together researchers and industry to explore unmet needs and exchange ideas, problems and solutions through roadmaps, workshops and conferences. We plan to invest in future scientists through our PhD and Post-Doc programs, and entrepreneurial training, to grow their expertise, help them better understand the commercial environment and encourage new start-ups.

LabGenius Ltd is a biopharmaceutical company based in London that focuses on discovering new biological molecules through the integration of artificial intelligence, automation, and synthetic DNA. Founded in 2012, the company has developed a robotic platform known as EVA, which acts as a robot scientist capable of designing, conducting, and learning from its own experiments. LabGenius specializes in developing next-generation protein therapeutics aimed at addressing unmet medical needs, including conditions like Inflammatory Bowel Disease. Their innovative approach utilizes advanced machine learning and synthetic biology to engineer the properties of protein drugs, enhancing attributes such as protease stability and tissue penetration. This technology enables the efficient creation of protein therapeutics, providing physicians with access to cutting-edge treatments developed through robotic automation.

Drill Surgeries empowers doctors operating on 20 million broken bones to reduce their 36% failure rate to <4% with Artificial Intelligence. Their AI-powered navigation system transforms trauma and orthopaedic procedures: 83% reduction in OR time Eliminate ALL unnecessary X-rays Save hospitals $2,000 per operation

AMPLY Discovery is a biotechnology company focused on utilizing machine learning and synthetic biology to discover novel drug and nutraceutical candidates. By employing a proprietary platform that combines in silico and in vitro approaches, AMPLY aims to develop first-in-class therapeutic molecules to address significant health challenges, including cancer, metabolic diseases, and multi-drug resistant infections. The company’s innovative engine digitizes the natural diversity of life, allowing for the identification of potential drug candidates based on their functional properties. This methodology enhances the predictability and cost-effectiveness of drug discovery, enabling research entities to uncover new treatments for difficult-to-treat diseases.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

Stemnovate Limited is a biotechnology company based in Cambridge, United Kingdom, founded in 2016. It specializes in providing innovative tools and technologies for drug screening and safety testing. Its offerings include induced pluripotent stem cells, human and multispecies primary cells, and a comprehensive cell culture and analysis package. The company utilizes advanced devices such as micro physiological systems and microfluidic designs to enhance drug discovery. One of its notable projects, "Liver on chip," focuses on liver toxicity testing and incorporates techniques like cellular reprogramming and organ-on-chip technology. Stemnovate also offers services in cell reprogramming, differentiation, and application development, catering to a diverse clientele that includes pharmacists, contract research organizations, small to medium enterprises, and academic institutions.

Awakn Life Sciences is a biotechnology company dedicated to developing and delivering psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company's team comprises chemists, scientists, psychiatrists, and psychologists who are working on the next generation of psychedelic drugs and therapies. By addressing AUD, a condition that affects millions worldwide and for which existing treatments are often insufficient, Awakn seeks to provide innovative therapeutic solutions for individuals struggling with addiction.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Sequential Skin and Sequential Bio fall under the umbrella of Sequential: The Skin Microbiome Testing Co™ Awarded the title "Most Significant" Testing Solution in the Industry - (Cosmetics & Toiletries, 2022), Sequential Bio is the skin microbiome company of the industry that specializes in microbiome testing and claims substantiation for brands formulating products for skin, scalp, vagina/vulva and oral care. Sequential offers a full end-to-end platform from study design, recruitment and testing, to analysis, and support on formulation development and certification. And it’s all done in vivo! Sequential Skin on the other hand is revolutionising skin health with the world's first consumer skin microbiome test. Formed of an award-winning team with a mission to empower individuals to make better-informed decisions about their skin health. (www.sequentialskin.com) Sequential is the product of the team's combined expertise in epigenetics, genetics, and microbiome research. Supported by Innovate UK, Enterprise SG, A*STAR, Genome Institute of Singapore, IndieBio New York, SOSV, Metaplanet, Scrum Ventures, CSB, and is a resident company of Johnson & Johnson Innovation – JLABS. Seen in Tatler, Cosmetic Designs, Tech Crunch, Genome Web, La Petite Journal, Global Wellness Summit, and Yahoo.

Neumind is a developer of technological solutions aimed at assisting individuals with neurological conditions and injuries. Founded in 2019 and based in Great Shelford, Cambridge, the company offers an app named Alfred, which provides both practical and therapeutic support to users and their caregivers. Alfred leverages smartphone technology to enhance cognitive functions, stimulate neural pathways, and promote behaviors and strategies grounded in neurorehabilitation and cognitive behavioral science. This application is designed to help individuals manage various neurological issues, such as brain injuries and dementia, enabling them to lead more independent, functional, and fulfilling lives.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they also developed their DNA randomisation technology, Short Sequence Randomisation™. In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock.

BoobyBiome is a company focused on improving infant health through microbiome research. It specializes in developing probiotic supplements specifically designed for infants with compromised microbiomes, particularly those born prematurely. By recreating the beneficial bacteria associated with breast milk, BoobyBiome aims to support healthy infant development. The company is also working on formula milk probiotics to create a substitute that closely resembles breast milk, allowing infants to receive the essential bacteria that contribute to their gut health and immune system.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.

Kynos Therapeutics is a biotechnology company focused on developing KMO inhibitors to address unmet medical needs in inflammation, immunity, and metabolism. The company aims to block the action of the enzyme KMO, which plays a crucial role in regulating systemic inflammation and is implicated in various medical conditions. By providing new therapies that target this key enzyme, Kynos Therapeutics seeks to offer innovative treatments for conditions where there is a significant demand for effective medicines.

GenoME Diagnostics is a biotechnology company focused on improving cancer detection through advanced blood testing technology. The company has developed the OvaME product, which enhances the standard CA125 blood tests, providing earlier detection and more accurate diagnoses of various cancers. By utilizing innovative techniques, GenoME Diagnostics aims to minimize misdiagnosis and reduce the likelihood of late detection, thereby enabling healthcare professionals to diagnose and treat patients more effectively.

Eleven Therapeutics is a biotechnology company focused on advancing RNA-based therapies through the integration of artificial intelligence and innovative drug development techniques. The company specializes in developing extended durability messenger RNA (mRNA) therapeutics aimed at addressing unmet medical needs in metabolic, endocrinologic, and infectious diseases. By employing proprietary high-throughput AI-enabled screening platforms, Eleven Therapeutics enhances the stability and targeted delivery of its therapeutic molecules. Its signature technology, SCSI-RNA, represents a programmable approach that allows for precise targeting of various diseases and biological targets. Through these advancements, Eleven Therapeutics is positioned to transform the landscape of RNA drug development, offering promising solutions for complex health challenges.

Sixfold Bioscience Inc. focuses on developing innovative drug delivery techniques aimed at treating cancer patients. Founded in 2018 and headquartered in London, the company specializes in programmable oligonucleotide delivery systems that target RNA specifically to diseased cells. This approach enhances the precision and effectiveness of cancer treatments, positioning Sixfold Bioscience as a significant player in the biotechnology sector.

We already know that upto 50% of patients struggle to take their medicines – patients are not well-supported and too often it remains a hidden problem until it's too late. CONNECT Care want to change that: empowering patients and, at the same time, using data-driven insights to enable clinicians and carers to provide better support in real-time.

Abtrace specializes in AI-based solutions designed to enhance medical expertise and streamline healthcare processes. The company focuses on developing clinical decision-making tools that transform the detection, monitoring, and treatment of chronic and long-term health conditions. By utilizing machine learning and big data techniques, Abtrace's software analyzes patient data to provide insights that help healthcare professionals manage current diseases and identify early signs of new conditions. This approach not only improves patient safety but also reduces the misuse of antibiotics and enhances treatment outcomes. Additionally, Abtrace's solutions automate key aspects of disease monitoring, enabling general practitioners and healthcare assistants to make informed decisions and deliver effective care while lowering practice costs and saving time.

Rinri Therapeutics Limited is a biotechnology company based in Sheffield, United Kingdom, focused on developing regenerative stem cell-based therapies to treat hearing loss. Founded in 2018, the company specializes in advanced stem cell technology that aims to repair damaged or dead sensory cells in the inner ear, specifically targeting sensorineural hearing loss. By restoring the cytoarchitecture of the inner ear, Rinri Therapeutics seeks to enable medical professionals to effectively restore hearing for affected patients.

AgPlus Diagnostics have developed a diagnostic platform technology that will deliver against the demanding market requirements of a true quantitative PoC product for use across a wide range of clinical applications.

Chromatwist specializes in the development of ultraviolet fluorescent dyes designed for bio-sensing and bio-imaging applications. Their innovative molecular technology platform allows for the creation of shifted organic fluorescent dyes that become visible when exposed to UV light, emitting across the entire visible color spectrum. These dyes are characterized by their unique aromatic organic structures, which incorporate donor and acceptor groups capable of absorbing UV light. This versatility enables their use in various diagnostic tests and advanced imaging techniques, including flow cytometry and multiphoton microscopy, thereby enhancing capabilities in the healthcare sector. Chromatwist's modular and scalable chemistry further supports the expansion of their product applications in the life sciences.

Glamorous AI develops an artificial intelligence-based drug discovery platform that focuses on low-data scenarios in pharmaceutical research. The platform utilizes AI to identify and optimize novel chemical compounds, facilitating the discovery of new medicines by analyzing prior experimental results. It is designed to handle sparse, noisy, and small datasets, making it particularly effective for tackling complex drug discovery challenges. By leveraging a large repository of pre-trained and customizable AI models, Glamorous AI enables researchers to screen extensive chemical libraries and address novel and first-in-class therapeutic targets, ultimately driving innovation in drug development and contributing to the advancement of treatments for various diseases.

Arecor Limited, based in Cambridge, United Kingdom, specializes in stabilization technology solutions for pharmaceutical and biotech companies. The company collaborates with these firms to enhance the commercial viability and usability of various proteins across multiple applications, including vaccines and therapeutic proteins. Arecor focuses on developing products for infectious diseases, diabetes, oncology, and autoimmune disorders, and aims to create high-concentration therapies that patients can self-administer at home. Notable projects include reformulating antibodies such as Trastuzumab and Rituximab for improved home treatment of breast cancer and non-Hodgkin’s lymphoma, respectively. Additionally, Arecor develops stable liquid formulations for vaccines and therapies that facilitate self-administration, addressing challenges related to stability and degradation. Founded in 2006, Arecor is recognized for its innovative formulation technology platform, which underpins its proprietary product portfolio and partnerships with industry leaders to advance biopharmaceutical development.

Senisca is a biotech start-up. They propose to create a new generation of oligonucleotide-based interventions to rewind the clock in old cells and target diseases and cosmetic signs of aging. They provide molecular and cellular biology and have patent-protected an innovation for the reversal of cellular senescence.

Camallergy Limited, based in Cambridge, United Kingdom, is a biopharmaceutical company established in 2015 that focuses on developing and manufacturing oral immunotherapy drugs and other pharmaceutical products specifically for food allergies. The company's primary offering is a novel oral immunotherapy designed to treat peanut allergies, which aims to provide patients with "bite-proof" protection within 14 weeks of therapy. This patient-centric treatment addresses the urgent needs of millions suffering from food allergies and is rooted in clinical research conducted at Cambridge University Hospitals NHS Foundation Trust. Camallergy's unique intellectual property and treatment regimen exemplify its commitment to improving the quality of life for individuals affected by these allergies.

CN Bio Innovations, formerly Zyoxel Ltd, is part of the Hong Kong-based, CN Innovations Holdings Limited (CNI). CN Bio develops human organ-on-a-chip platforms for the testing and development of therapeutics for serious human diseases. The company’s leading organ-on-chip disease model is a full viral lifecycle model of hepatitis B (HBV) based on the culture of primary human hepatocytes in the company’s proprietary LiverChip platform. The HBV disease model, which is referred to as Quantum-B, is currently being deployed in drug discovery and research alliances with several leading pharmaceutical and biotech companies. Working closely with academic pioneers in the bio-engineering field, and backed by prestigious grant awards from sponsors including the United States Defence Advanced Research Projects Agency and UK Technology Strategy Board, CN Bio continues to develop next-generation organ-on-chips which will improve the quality of life for millions of people around the world by fast-tracking breakthrough therapies to market.

Aramune Technologies focuses on creating natural, plant-derived feed materials that can be integrated with conventional animal feeds to replace antimicrobial agents and foster growth. The company is dedicated to developing infection prevention technologies that offer sustainable alternatives to harmful ingredients in both animal and consumer healthcare products. Through laboratory-scale isolation, Aramune generates a natural, orally available compound that is free of endotoxins and non-toxic. This innovation aims to prevent infections in livestock, companion animals, and humans, thereby helping farmers reduce the incidence of diseases and infections in their animals.

Oxford Endovascular is focused on developing an innovative medical device for the treatment of brain aneurysms. The company's technology employs a laser-cut metal alloy with shape-memory properties, which can be inserted into a patient's brain via a catheter. Once in place, the device expands into a tiny mesh tube, known as a flow diverter, that conforms to the natural shape of the blood vessel. This design effectively diverts blood flow away from the aneurysm, facilitating its healing and reducing the risk of rupture. By utilizing advanced origami engineering, Oxford Endovascular aims to enhance patient outcomes and improve survival rates for those affected by intracranial aneurysms.

Ingenion Medical is a medical device company. The Company specializes in creating innovative, clinically relevant, and cost-effective solutions to problems of urinary flow and control.

Abtrace specializes in AI-based solutions designed to enhance medical expertise and streamline healthcare processes. The company focuses on developing clinical decision-making tools that transform the detection, monitoring, and treatment of chronic and long-term health conditions. By utilizing machine learning and big data techniques, Abtrace's software analyzes patient data to provide insights that help healthcare professionals manage current diseases and identify early signs of new conditions. This approach not only improves patient safety but also reduces the misuse of antibiotics and enhances treatment outcomes. Additionally, Abtrace's solutions automate key aspects of disease monitoring, enabling general practitioners and healthcare assistants to make informed decisions and deliver effective care while lowering practice costs and saving time.

NovaBiotics Ltd. is a clinical-stage biotechnology company based in Aberdeen, United Kingdom, with an additional location in Raleigh, North Carolina. Founded in 2004, the company specializes in the design and development of innovative anti-infective therapies for medically unmet diseases. Its product pipeline includes Novexatin, a cationic antifungal peptide for treating onychomycosis, and Lynovex, a dual-therapy for cystic fibrosis-related lung diseases. Additionally, NovaBiotics offers other antifungal peptides such as Novamycin for conditions like aspergillosis and cryptococcosis, as well as Novarifyn, an antibacterial peptide targeting bacterial infections. The company’s proprietary anti-infective peptide platform allows for the development of both antifungal and antibacterial candidates, addressing serious health challenges related to drug-resistant infections.

BeneTalk is a digital speech therapy application designed to assist individuals who stutter in communicating more confidently and comfortably. The app functions similarly to a fitness tracker, enabling users to learn and practice new speaking habits during everyday conversations. It monitors key aspects of speech, such as breathing and speech patterns, while providing real-time feedback and tracking performance history. This feature aims to enhance the quality of life for individuals who stutter and their families by helping them address speech and language difficulties effectively.

Atelerix Limited, based in Cambridge, United Kingdom, specializes in the storage and transportation of viable cells and tissues at room temperature. Founded in 2006, the company has developed a patented technology that utilizes alginate hydrogels to encapsulate biological products, protecting them from biochemical and physical damage during storage and shipping. This innovative approach eliminates the need for cryopreservation, making it easier for customers to use cells and assays immediately upon arrival without the risk of cytotoxicity or damage. Atelerix's technology enhances predictability and reliability in drug discovery models and cell therapies, allowing for the safe storage and transport of suspended and planted cells, as well as tissues and stem cells.

AgPlus Diagnostics have developed a diagnostic platform technology that will deliver against the demanding market requirements of a true quantitative PoC product for use across a wide range of clinical applications.

DIOSynVax is a vaccine antigen design company that focuses on accelerating vaccine development to enhance protection against both existing and emerging pathogens. By utilizing innovative technology, DIOSynVax digitally designs, optimizes, and synthesizes vaccines, leading to significant advancements in immunization against diseases such as influenza, COVID-19, and viral hemorrhagic fevers. The company's approach aims to improve the efficacy of vaccines, enabling healthcare professionals to treat patients more effectively and facilitate quicker recovery from various viral infections.

Reflection Therapeutics is developing cell therapy technology against neuroinflammation across the board.

Directed Systems specializes in developing medical software that enhances clinical decision-making through real-time patient monitoring. The company focuses on creating intuitive applications designed with input from medical professionals, particularly anesthesiologists. Their flagship product, the FDA-cleared HDA™, assists in managing cardiovascular health during surgery by continuously monitoring arterial pressure and providing situational awareness through a single, comprehensive screen. Directed Systems aims to optimize clinical performance in time-critical situations, while their platform is also building a substantial dataset that utilizes analytics and AI tools to further improve patient outcomes and reduce complications in various healthcare settings, including recovery and intensive care.

Newrotex is an Oxford-based SME that has developed an off-the-shelf silk-based conduit for the repair of peripheral nerve injuries with IP granted.

Closed Loop Medicine Ltd is a healthcare technology company based in Cambridge, United Kingdom, focused on developing innovative solutions that combine prescription drugs with digital therapies. Founded by a team of experienced healthcare professionals and life scientists, the company aims to optimize medication dosing through real-time feedback and linked behavioral therapy to enhance patient outcomes. Currently, Closed Loop Medicine is developing products targeting hypertension and insomnia, alongside a diverse pipeline addressing various chronic diseases. The company prioritizes the needs of both patients and clinicians in the design and development of its offerings, striving to integrate technology effectively within the healthcare system.

QV Bioelectronics is focused on improving the lives of brain tumor patients through its innovative electric field therapy implant, GRACE. Developed in collaboration with leading neurosurgeons in the UK, GRACE aims to extend the life expectancy of glioblastoma patients, a group historically faced with limited treatment options and poor survival rates. Recognizing the urgent need for effective therapies, co-founders Dr. Richard Fu and Dr. Chris Bullock created a solution to address both the clinical and quality of life challenges faced by patients. The company has garnered nearly $1 million in funding from UK institutions, including Innovate UK, and over $1 million in equity funding from international life science investors. With a multidisciplinary team based in Alderley Park, Cheshire, QV Bioelectronics is dedicated to advancing GRACE from research to clinical application, utilizing cutting-edge materials science to enhance treatment outcomes for patients.

Medwise.ai offers a customizable search platform designed to support clinical decision-making for healthcare professionals. Utilizing natural language processing and artificial intelligence, the platform enables doctors to efficiently access and organize medical knowledge. By leveraging real-world data, Medwise.ai provides valuable intelligence and insights to various stakeholders within the healthcare ecosystem. This innovative approach aims to enhance the professional capabilities of doctors, ultimately improving patient care and outcomes.

ONKO is a provider of unified cancer care. ONKO combines digital technology with the support of healthcare professionals to provide patients with personalised expertise from cancer dietitians, physiotherapists, specialist nurses and psychologists.

Newrotex is an Oxford-based SME that has developed an off-the-shelf silk-based conduit for the repair of peripheral nerve injuries with IP granted.